Literature DB >> 22467925

High-dose intravenous immunoglobulin treatment increases regulatory T cells in patients with eosinophilic granulomatosis with polyangiitis.

Naomi Tsurikisawa1, Hiroshi Saito, Chiyako Oshikata, Takahiro Tsuburai, Kazuo Akiyama.   

Abstract

OBJECTIVE: We studied the effects of intravenous immunoglobulin (IVIG) treatment on clinical symptoms and regulatory T (Treg) cell frequency in patients with eosinophilic granulomatosis with polyangiitis (EGPA).
METHODS: Twenty-two EGPA patients with severe mononeuritis multiplex or cardiac dysfunction received IVIG therapy combined with conventional therapy (corticosteroid, immunosuppressants, or both). As a control, 24 EGPA patients without severe vasculitic symptoms were treated with conventional therapy. Before, during, and after treatment, we determined percentages of Treg cells and other relevant cells in patients' peripheral blood.
RESULTS: The frequency of CD25+ among CD4+ T cells was lower at onset in the study group than in controls but increased significantly after IVIG treatment, relative to controls. The frequency of CD25+ among CD4+ T cells correlated with the frequency of FOXP3+ among CD4+ T cells and interleukin 10 produced by CD25+CD4+ T cells.
CONCLUSION: The increase in Treg cells seen with the combination of IVIG and conventional therapy may promote remission in EGPA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22467925     DOI: 10.3899/jrheum.110981

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

1.  Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barré syndrome patients.

Authors:  Mohan S Maddur; Magalie Rabin; Pushpa Hegde; Francis Bolgert; Moneger Guy; Jean-Michel Vallat; Laurent Magy; Jagadeesh Bayry; Srini V Kaveri
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

Review 2.  Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute.

Authors:  Miglena G Prabagar; Hyeong-jwa Choi; Jin-Yeon Park; Sohee Loh; Young-Sun Kang
Journal:  Clin Exp Med       Date:  2013-09-01       Impact factor: 3.984

3.  Intravenous immunoglobulin-mediated expansion of regulatory T cells in autoimmune patients is associated with increased prostaglandin E2 levels in the circulation.

Authors:  Mohan S Maddur; Jamma Trinath; Magalie Rabin; Francis Bolgert; Moneger Guy; Jean-Michel Vallat; Laurent Magy; Kithiganahalli N Balaji; Srini V Kaveri; Jagadeesh Bayry
Journal:  Cell Mol Immunol       Date:  2014-12-08       Impact factor: 11.530

Review 4.  Differences in Anti-Inflammatory Actions of Intravenous Immunoglobulin between Mice and Men: More than Meets the Eye.

Authors:  Angela S W Tjon; Rogier van Gent; Teunis B Geijtenbeek; Jaap Kwekkeboom
Journal:  Front Immunol       Date:  2015-04-28       Impact factor: 7.561

5.  High-dose intravenous immunoglobulin therapy for eosinophilic granulomatosis with polyangiitis.

Authors:  Naomi Tsurikisawa; Hiroshi Saito; Chiyako Oshikata; Takahiro Tsuburai; Kazuo Akiyama
Journal:  Clin Transl Allergy       Date:  2014-12-12       Impact factor: 5.871

6.  Th17 cells reflect colon submucosal pathologic changes in active eosinophilic granulomatosis with polyangiitis.

Authors:  Naomi Tsurikisawa; Chiyako Oshikata; Takahiro Tsuburai; Satoshi Sugano; Yoko Nakamura; Takuya Shimoda; Shunpei Tamama; Ken Adachi; Ayako Horita; Ikuo Saito; Hiroshi Saito
Journal:  BMC Immunol       Date:  2015-12-29       Impact factor: 3.615

7.  Impact of intravenous immunoglobulin on the dopaminergic system and immune response in the acute MPTP mouse model of Parkinson's disease.

Authors:  Isabelle St-Amour; Mélanie Bousquet; Isabelle Paré; Janelle Drouin-Ouellet; Francesca Cicchetti; Renée Bazin; Frédéric Calon
Journal:  J Neuroinflammation       Date:  2012-10-09       Impact factor: 8.322

Review 8.  Induction of Regulatory T Cells by Intravenous Immunoglobulin: A Bridge between Adaptive and Innate Immunity.

Authors:  Gabriel N Kaufman; Amir H Massoud; Marieme Dembele; Madelaine Yona; Ciriaco A Piccirillo; Bruce D Mazer
Journal:  Front Immunol       Date:  2015-09-11       Impact factor: 7.561

Review 9.  Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics.

Authors:  Anne S De Groot; Frances Terry; Leslie Cousens; William Martin
Journal:  Expert Rev Clin Pharmacol       Date:  2013-11       Impact factor: 5.045

Review 10.  Engineering of Fc Multimers as a Protein Therapy for Autoimmune Disease.

Authors:  Elizabeth A Fitzpatrick; Jin Wang; S E Strome
Journal:  Front Immunol       Date:  2020-03-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.